Make Informed Investment Decisions with Affordable Access to Experts
A 6th View: Discussing GBT's recent Sickle Cell Phase 3 HOPE Results for Voxelotor (Previously GBT440)Ticker(s): GBT, Emmaus Life Sciences
Name: Dr Alan R. Cohen - MD
Institution: Children's Hospital of Philadelphia
- Professor of Pediatrics at the Perelman School of Medicine, University of Pennsylvania (Penn) and the Children’s Hospital of Philadelphia (CHOP).
- Currently manages 30 patients with sickle cell disease.
- Research interests have focused on thalassemia, sickle cell disease, and transfusional iron overload; he has developed novel approaches to transfusion therapy to reduce the rate of iron accumulation, has led clinical trials of the currently licensed iron chelators, and more than 100 publications are original papers in major journals such as NEJM.
Please describe your background and experience with Sickle Cell Disease and any work with Voxelotor.Added By: c_admin
What is your high level opinion of today's top-line HOPE trial data?Added By: c_admin
On a scale of 1-10 how excited about this program are you for patients?Added By: c_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.